On the stock market since 2003, it operates in the world of health and science. It has 103,249 employees. Now — the numbers.
This is an established company with proven profits.
No real growth.
The gap is $17.7B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
The net profit margin is 20% — still a thick cushion, though costs have been eating into it lately.
It pays out $1.55 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 1% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The price action doesn’t yet back an upward turn. Council score: 3/10.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, RHHBY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: RHHBY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.